We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Pt(II)‐Phenanthroline‐Ln(III)‐DOTA d–f Hybrids as Small‐Molecule Theranostics.
- Authors
Brito, Beatriz; Price, Thomas W.; Bañobre‐López, Manuel; Gallo, Juan; Stasiuk, Graeme J.
- Abstract
1,10‐Phenanthroline d‐ or f‐metal complexes can be utilised in biomedical applications such as imaging or therapeutics. Herein, we designed bimetallic d‐block metal‐phenanthroline f‐block metal‐1,4,7,10‐tetraazacyclododecane‐1,4,7,1,0‐tetraacetic acid (DOTA) conjugates as theranostic agents to simultaneously achieve both of these applications. Luminescence studies show the 1,10‐phenanthroline‐Eu(III)‐DOTA complexes displayed an off/on/off pH‐dependent switch, demonstrating their potential as pH‐responsive lanthanide luminescence probes. Relaxometry studies showed that the 1,10‐phenanthroline‐Gd(III)‐DOTA complexes present a r1 of 5.15±0.05 mM−1 s−1 and could thus be used as magnetic resonance (MR) contrast agents. Complexation of Pt(II) by the 1,10‐phenanthroline moiety resulted in quenching of the Eu(III) luminescence, but an enhancement of the Gd(III) relaxivity (r1=7.53±0.69 mM−1 s−1). Cell viability studies of the d–f hybrids in a cancer cell line showed the potential of these complexes as anticancer agents, as the IC50 for the Pt(II)/Gd(III) complex (IC50=24.9 μM) was lower than that of cisplatin (IC50=31.6 μM). As such, Pt(II)‐1,10‐phenanthroline‐Gd(III)‐DOTA complexes are promising theranostic agents for cancer therapy.
- Subjects
PLATINUM; COMPANION diagnostics; CONTRAST media; MAGNETIC resonance; CANCER treatment; ANTINEOPLASTIC agents
- Publication
European Journal of Inorganic Chemistry, 2024, Vol 27, Issue 17, p1
- ISSN
1434-1948
- Publication type
Article
- DOI
10.1002/ejic.202400063